Why Becton Dickinson Stock Is Trading Higher Today?
Portfolio Pulse from Vandana Singh
The FDA has approved Becton Dickinson's (BDX) BD Alaris Infusion System with 510(k) clearance, allowing the company to return to full commercial operations. The clearance covers updated hardware features and a new software version with enhanced cybersecurity. The company expects to begin shipping devices and recognizing revenue in FY24 and does not expect any material incremental revenue contribution for the remainder of FY23. BDX shares are up 6.48% in premarket trading.
July 24, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FDA approval of Becton Dickinson's BD Alaris Infusion System is a positive development for the company, potentially boosting its stock price in the short term.
The FDA approval allows Becton Dickinson to return to full commercial operations for its BD Alaris Infusion System, which had previously been recalled. This is a significant positive development for the company, likely to boost investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100